ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up (AMIAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03166696
Recruitment Status : Active, not recruiting
First Posted : May 25, 2017
Last Update Posted : May 25, 2017
Sponsor:
Information provided by (Responsible Party):
Wei Shi, Guangdong General Hospital

Brief Summary:
A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.

Condition or disease
Myocardial Infarction Cerebral Infarction Chronic Kidney Diseases Mortality

Study Type : Observational [Patient Registry]
Estimated Enrollment : 30000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: The Registry and Follow-up of Patients With Acute Myocardial Infarction or Acute Cerebral Infarction
Actual Study Start Date : January 3, 2000
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Group/Cohort
acute cerebral infarction
the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
acute myocardial infarction
the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction



Primary Outcome Measures :
  1. all-cause mortality [ Time Frame: follow up until the study end (May 2018,Anticipated) ]
    all-cause mortality


Secondary Outcome Measures :
  1. kidney outcome [ Time Frame: follow up until the study end (May 2018,Anticipated) ]
    ESRD or 50%eGFR decline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
the consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016.
Criteria

Inclusion Criteria:

  • consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction

Exclusion Criteria:

  • lacunar infarction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03166696


Locations
China, Guangdong
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080
the First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China, 510405
Yue Bei People's Hospital
Shaoguan, Guangdong, China, 512025
Sponsors and Collaborators
Guangdong General Hospital
Investigators
Study Director: Liming Yao, M.D. Guangdong General Hospital

Responsible Party: Wei Shi, Professor, Guangdong General Hospital
ClinicalTrials.gov Identifier: NCT03166696     History of Changes
Other Study ID Numbers: 20170309
First Posted: May 25, 2017    Key Record Dates
Last Update Posted: May 25, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Infarction
Kidney Diseases
Myocardial Infarction
Renal Insufficiency, Chronic
Cerebral Infarction
Ischemia
Pathologic Processes
Necrosis
Urologic Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Renal Insufficiency
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Stroke